The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer
Open accessAbstract
Background: The features and survival of stage IV breast cancer patients with different metastatic sites are poorly understood. This study aims to examine the clinicopathological features and survival of stage IV breast cancer patients according to different metastatic sites. Methods: Using the Surveillance, Epidemiology, and End Results database, we restricted our study population to stage IV breast cancer patients diagnosed between 2010 to 2015. The clinicopathological features were examined by chi-square tests. Breast cancer-specific survival (BCSS) and overall survival (OS) were compared among patients with different metastatic sites by the Kaplan-Meier method with log-rank test. Univariable and multivariable analyses were also performed using the Cox proportional hazard model to identify statistically significant prognostic factors. Results: A total of 18,322 patients were identified for survival analysis. Bone-only metastasis accounted for 39.80% of patients, followed by multiple metastasis (33.07%), lung metastasis (10.94%), liver metastasis (7.34%), other metastasis (7.34%), and brain metastasis (1.51%). The Kaplan-Meier plots showed that patients with bone metastasis had the best survival, while patients with brain metastasis had the worst survival in both BCSS and OS ( p < 0.001, for both). Multivariable analyses showed that age, race, marital status, grade, tumor subtype, tumor size, surgery of primary cancer, and a history of radiotherapy or chemotherapy were independent prognostic factors. Conclusion: Stage IV breast cancer patients have different clinicopathological characteristics and survival outcomes according to different metastatic sites. Patients with bone metastasis have the best prognosis, and brain metastasis is the most aggressive subgroup.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Nomograms in oncology: more than meets the eye
Balachandran, V. P., Gonen, M., Smith, J. J., & DeMatteo, R. P. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71116-7 · Cited by 3,292
Breast cancer statistics, 2019
DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21583 · Cited by 3,114
Metastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Ma, J., & Jemal, A. (2013) · Breast Cancer Metastasis and Drug Resistance · doi:10.1007/978-1-4614-5647-6_1 · Cited by 1,907
Cancer epidemiology biomarkers & prevention
Press, H. (1991) · Cited by 1,398
Breast Cancer Research and Treatment
Alexander, M. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006151427889 · Cited by 997
Badwe, R., Hawaldar, R., Nair, N., Kaushik, R., Parmar, V., Siddique, S., Budrukkar, A., Mittra, I., & Gupta, S. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00135-7 · Cited by 592
Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States
Mariotto, A. B., Etzioni, R., Hurlbert, M., Penberthy, L., & Mayer, M. (2017) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0889 · Cited by 529
Cited by
The lingering mysteries of metastatic recurrence in breast cancer
Riggio, A. I., Varley, K. E., & Welm, A. L. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01161-4 · Cited by 616
Wang, J., Liang, S., Chen, S., Ma, T., Chen, M., Niu, C., Leng, Y., & Wang, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02619-w · Cited by 53
Acetylation of histone H3 in cancer progression and prognosis
Miziak, P., Baran, M., Borkiewicz, L., Trombik, T., & Stepulak, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010982 · Cited by 49
Joe, N. S., Godet, I., Milki, N., Ain, N. U. I., Oza, H. H., Riggins, G. J., & Gilkes, D. M. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01591-3 · Cited by 24
Blancas, I., Olier, C., Conde, V., Bayo, J. L., Herrero, C., Zarcos-Pedrinaci, I., Carabantes, F., Baena-Cañada, J. M., Cruz, J., & Ruiz-Borrego, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-83622-1 · Cited by 12
Metadata
- Authors
- Wang, R., Zhu, Y., Liu, X., Liao, X., He, J., & Niu, L.
- Venue
- BMC Cancer
- Published
- 2019-11-12
- Volume
- 19
- Issue
- 1
- Pages
- 1091-1091
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2988364315
- Cited by
- 459
- References
- 25
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. https://app.cochat.ai/papers/10.1186/s12885-019-6311-z
- The paper
- Wang, R., Zhu, Y., Liu, X., Liao, X., He, J., & Niu, L. (2019). The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. https://doi.org/10.1186/s12885-019-6311-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
